Newsroom der German Breast Group
In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
17.02.2021 OlympiA trial crossed superiority boundary for invasive disease-free survival
IDMC has concluded that OlympiA trial crossed superiority boundary for invasive disease-free survival vs. placebo at planned interim analysis. OlympiA Phase III trial of Lynparza in the adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer will be analysed and reported early.
17.02.2021 REGISTRIERUNG/ ANMELDUNG GBG Jahrestreffen 2021
GBG Jahrestreffen vom 24. bis 26. Februar 2021 wissenschaftliche Veranstaltung
04.02.2021 December 2020: Effect of germline BRCA1/2 mutations on haematological toxicities after neoadjuvant chemotherapy.
A retrospective analysis investigating the effect of germline BRCA1/2 mutations on severe haematological toxicities in TNBC patients treated with chemotherapy has been published in European Journal of Cancer.
28.01.2021 BIGPICTURE - Pathology Image Repository
A new consortium of the EU Innovative Medicines Initiative (IMI) will establish the biggest database of pathology images to accelerate the development of artificial intelligence in medicine.
21.01.2021 Covid-Impfung unter Chemotherapie
Entscheidungshilfen zur Durchführung einer COVID-19-Impfung bei Studienpatienten.
04.01.2021 AGO-Mamma State of the Art Meeting
Save the date: Virtuelles State of the Art Meeting am 27. Februar.
11.12.2020 November 2020: Effect of neoadjuvant chemotherapy on immune system in patients with TNBC
A translational research project evaluating effect of chemotherapy on different immune subsets in TNBC patients from GeparNuevo trial was published in Journal for ImmunoTherapy of Cancer
09.12.2020 GBG Research at SABCS Virtual Meeting 2020
Data on GBG study PenelopeB and several collaborative projects will be presented at the SABCS Virtual Meeting 2020.
13.11.2020 October 2020: Results from GeparOLA study
We are delighted to inform you that results from GeparOLA trial have been published in Annals of Oncology.
07.11.2020 GeparDouze-1000ste Patient randomisiert!
NSABP und GBG freuen sich bekannt zu geben, dass der 1000. Patient für die GeparDouze-Studie randomisiert wurde.
23.10.2020 September 2020: Clinical Outcome of Breast Cancer Patients with asymptomatic brain metastases.
Analysis of breast cancer patients with asymptomatic brain metastases from BMBC registry has been published in Cancers (Basel).
23.10.2020 August 2020: MGMT promoter methylation in TNBC
A translational research project evaluating the MGMT promoter methylation status in TNBC from GeparSixto has been published in PLoSOne
09.10.2020 ICH BIN DABEI! Brustkrebs verstehen.
Kampagne „ICH BIN DABEI! Brustkrebs verstehen – wir unterstützen die Veranstaltung!
09.10.2020 PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint
PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival in women with hormone receptor-positive, human epidermal growth factor-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy. No unexpected safety signals were observed.
14.09.2020 GBG Research at ESMO Virtual Meeting 2020
Data of several GBG studies was presented at the upcoming ESMO Virtual Meeting 2020, which took place from 19 to 21 September 2020.
22.07.2020 Gleiche Heilungschancen, mehr Lebensqualität?
Große internationale Multicenter-Studie (TAXIS) vergleicht zwei chirurgische Therapiekonzepte bei Brustkrebs mit Lymphknotenbefall / Prof. Dr. Jörg Heil
14.07.2020 July 2020: Tumor mutational burden and immune gene expression in GeparNuevo trial
A research project investigating tumor mutational burden and immune gene expression profile for response to neoadjuvant treatment in early TNBC has been published in Annals of Oncology
16.06.2020 June 2020: Central review of INSEMA radiotherapy planning
We are delighted to inform you that results from a quality assurance process integrated into the INSEMA trial have been published in International Journal of Radiation Oncology, Biology, Physics.
30.05.2020 Update on PALLAS, an International Academic Breast Cancer Study Evaluating Adjuvant Palbociclib
Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence
